Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVG-291 in Chronic Spinal Cord Injury (RESTORE)
NCT07799532Phase 3Recruiting
- Sponsor
- NervGen Pharma Corp.
- Start
- Sep 2026
- Primary completion
- Jul 2027
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in spinal cord injury (SCI) comparing NVG-291 Arm with Placebo Arm (2 arms). Primary endpoint: Graded and Redefined Assessment of Strength, Sensibility and Prehension Quantitative Prehension score at 12 weeks. Started Sep 2026; status: recruiting.
02
Drugs
NVG-291
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT07799532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07799532.